It’s time to submit your most outstanding emerging studies. The late-breaking abstract category allows for the submission of truly late-breaking, high-impact scientific research for which no preliminary data were available at the time of the June 5 general abstract submission deadline. Late-breaking abstracts should present data that are high impact, groundbreaking, innovative and newsworthy. Late-breaking…
Heated Gloves May Improve Hand Function in Diffuse Systemic Sclerosis
Systemic sclerosis (SSc), a subtype of scleroderma, is a rare, complex autoimmune disease characterized by widespread vasculopathy of the small arteries and fibroblast dysfunction.1,2 It has been described as a fibrosing microvascular disease, because vascular injury precedes and leads to tissue fibrosis.3 The resulting Raynaud’s phenomenon, pain, skin thickening and tightening, and multi-organ involvement have…
Effectiveness of Retinoic Acid, Hydroxychloroquine Examined for Hand OA
The Osteoarthritis Research Society International (OARSI) held the 2017 OARSI World Congress in Las Vegas, April 27–30. Below, we report on two of the sessions held. Retinoic Acid & Hand Osteoarthritis Retinoic acid is a vitamin A derivative and hormonal signaling molecule with a role in cartilage and skeletal development. Retinoic acid has complex function,…
Rheumatology Research Clears Paths to Improved Arthritis Patient Care, Long-Term Health
WASHINGTON, D.C.—Rheumatology researchers look for next-generation treatments, healthy interventions, and genetic and microbial clues to disease pathogenesis and therapy response, according to new studies presented at a Nov. 15, 2016, press conference at the 2016 ACR/ARHP Annual Meeting. OA & Physical Function How do you know when a patient with knee osteoarthritis (OA) has the…
2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
SAN FRANCISCO—Rheumatologists have to look no further than the American College of Rheumatology guidelines to know that the options for patients with lupus nephritis are sometimes not very appealing. The first-line choices are either mycophenolate mofetil (MMF) plus glucocorticoids or cyclophosphamide (CYC), also with glucocorticoids—and all of their attendant side effects. The problem: evidence, said…